6-(4'-hydroxy-3'-methoxyphenyl)hexanoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 6-(4'-hydroxy-3'-methoxyphenyl)hexanoic acid
• 英文别名: 6-(4-Hydroxy-3-methoxyphenyl)hexanoic acid
• 化学式: C₁₃H₁₈O₄
• 分子量: 238.284
• InChiKey: SDESBGJMRHLYBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(4'-hydroxy-3'-methoxyphenyl)hexanoic acid 在 二异丁基氢化铝 作用下， 以 甲醇 、 正己烷 、 二氯甲烷 、 甲苯 为溶剂， 反应 55.0h， 生成 4-(6-((2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(propyl)amino)hexyl)-2-methoxyphenol
  参考文献：
  名称：

  Novel multifunctional dopamine D 2 /D 3 receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties

  摘要：

  Our ongoing drug development endeavor to design compounds for symptomatic and neuroprotective treatment of Parkinson's disease (PD) led us to carry out a structure activity relationship study based on dopamine agonists pramipexole and 5-OHDPAT. Our goal was to incorporate structural elements in these agonists in a way to preserve their agonist activity while producing inhibitory activity against aggregation of alpha-synuclein protein. In our design we appended various catechol and related phenol derivatives to the parent agonists via different linker lengths. Structural optimization led to development of several potent agonists among which (-)-8a, (-)-14 and (-)-20 exhibited potent neuroprotective properties in a cellular PD model involving neurotoxin 6-OHDA. The lead compounds (-)-8a and (-)-14 were able to modulate aggregation of alpha-synuclein protein efficiently. Finally, in an in vivo PD animal model, compound (-)-8a exhibited efficacious anti-parkinsonian effect. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.08.021
• 作为产物：
  描述：

  4-羧丁基三苯基溴化膦 在 palladium 10% on activated carbon 、 氢气 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， 反应 27.0h， 生成 6-(4'-hydroxy-3'-methoxyphenyl)hexanoic acid
  参考文献：
  名称：

  Novel multifunctional dopamine D 2 /D 3 receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties

  摘要：

  Our ongoing drug development endeavor to design compounds for symptomatic and neuroprotective treatment of Parkinson's disease (PD) led us to carry out a structure activity relationship study based on dopamine agonists pramipexole and 5-OHDPAT. Our goal was to incorporate structural elements in these agonists in a way to preserve their agonist activity while producing inhibitory activity against aggregation of alpha-synuclein protein. In our design we appended various catechol and related phenol derivatives to the parent agonists via different linker lengths. Structural optimization led to development of several potent agonists among which (-)-8a, (-)-14 and (-)-20 exhibited potent neuroprotective properties in a cellular PD model involving neurotoxin 6-OHDA. The lead compounds (-)-8a and (-)-14 were able to modulate aggregation of alpha-synuclein protein efficiently. Finally, in an in vivo PD animal model, compound (-)-8a exhibited efficacious anti-parkinsonian effect. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.08.021

文献信息

• COMPOSITIONS FOR CORRECTING AGE RELATED CHANGES OF A HUMAN ENDOCRINE SYSTEM AND METHODS FOR PRODUCING A PHARMACEUTICAL FORM BASES ON SAID COMPOSITIONS
  申请人：Obschestvo S Ogranichennoi Otvetstvennostyu "Rusgen"

  公开号：EP1752155A1

  公开（公告）日：2007-02-14

  The present invention relates to anti-aging pharmacology and is intended for correction of age-related changes in human endocrine system. The essence of the invention is the compositions for correction of certain age-related endocrine changes and method for production of pharmaceutical form based thereon. Each composition contains a mixture of substances exhibiting hormonal activity (HA) or hormone-like activity (HLA) selected from the group: C21 or C 19 steroids, pregnenolone, 17-hydroxypregnenolone, DHEA, progesterone, testosterone, or a hormone-like substance of herbal origin (HS), and also a dry methanolic of Nettle root extract, taken in a definite ratio, wherein HA, HLA or HS with the Nettle root extract can further contain a Deer Antler velvet extract and/or Ginseng root extract, and HS can comprise diosgenin or protodioscin. One variant of the composition is a mixture of a dry Ginseng root extract and a dry Nettle root extract. The inventive method for production of said pharmaceutical form consists in mixing an active component and pharmaceutically acceptable carrier with suitable adjuvants in an effective amount. The useful result is in broadening the range of natural agents able to correct age-related hormonal changes in human organism.

  本发明涉及抗衰老药理学，用于纠正人体内分泌系统与年龄有关的变化。本发明的实质是用于纠正某些与年龄有关的内分泌变化的组合物以及基于这些组合物的药剂的生产方法。每种组合物都含有从以下组别中选出的具有荷尔蒙活性（HA）或类荷尔蒙活性（HLA）的物质的混合物：C21或C19类固醇、孕烯醇酮、17-羟基孕烯醇酮、DHEA、孕酮、睾酮或草本来源的激素样物质（HS），以及按一定比例提取的荨麻根提取物的甲醇干品，其中HA、HLA或HS与荨麻根提取物可进一步含有鹿茸提取物和/或人参根提取物，HS可包括薯蓣皂苷或原薯蓣皂苷。组合物的一种变体是干人参根提取物和干荨麻根提取物的混合物。本发明生产所述药剂的方法包括将活性成分和药学上可接受的载体与适当的佐剂以有效量混合。本发明的有益成果是扩大了能够纠正人类机体中与年龄有关的荷尔蒙变化的天然制剂的范围。
• Fluorescent microsphere-based lateral-flow immunoassay for rapid and sensitive determination of eugenols
  作者：Xianlu Lei、Xinxin Xu、Li Wang、Liqiang Liu、Hua Kuang、Liguang Xu、Chuanlai Xu

  DOI：10.1016/j.foodchem.2023.135475

  日期：2023.6
• Compositions for Correcting Age Related Changes of a Human Endocrine System and Methods for Producing a Pharmaceutical Form Bases on Said Compositions
  申请人：Musaeva Adilya Rafik kyzy

  公开号：US20090011041A1

  公开（公告）日：2009-01-08

  The present invention relates to anti-aging pharmacology and is intended for correction of age-related changes in human endocrine system. The essence of the invention is the compositions for correction of certain age-related endocrine changes and method for production of pharmaceutical form based thereon. Each composition contains a mixture of substances exhibiting hormonal activity (HA) or hormone-like activity (HLA) selected from the group: C21 or C19 steroids, pregnenolone, 17-hydroxypregnenolone, DHEA, progesterone, testosterone, or a hormone-like substance of herbal origin (HS), and also a dry methanolic of Nettle root extract, taken in a definite ratio, wherein HA, HLA or HS with the Nettle root extract can further contain a Deer Antler velvet extract and/or Ginseng root extract, and HS can comprise diosgenin or protodioscin. One variant of the composition is a mixture of a dry Ginseng root extract and a dry Nettle root extract. The inventive method for production of said pharmaceutical form consists in mixing an active component and pharmaceutically acceptable carrier with suitable adjuvants in an effective amount. The useful result is in broadening the range of natural agents able to correct age-related hormonal changes in human organism.
• Novel multifunctional dopamine D 2 /D 3 receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties
  作者：Dan Luo、Horrick Sharma、Deepthi Yedlapudi、Tamara Antonio、Maarten E.A. Reith、Aloke K. Dutta

  DOI：10.1016/j.bmc.2016.08.021

  日期：2016.11

  Our ongoing drug development endeavor to design compounds for symptomatic and neuroprotective treatment of Parkinson's disease (PD) led us to carry out a structure activity relationship study based on dopamine agonists pramipexole and 5-OHDPAT. Our goal was to incorporate structural elements in these agonists in a way to preserve their agonist activity while producing inhibitory activity against aggregation of alpha-synuclein protein. In our design we appended various catechol and related phenol derivatives to the parent agonists via different linker lengths. Structural optimization led to development of several potent agonists among which (-)-8a, (-)-14 and (-)-20 exhibited potent neuroprotective properties in a cellular PD model involving neurotoxin 6-OHDA. The lead compounds (-)-8a and (-)-14 were able to modulate aggregation of alpha-synuclein protein efficiently. Finally, in an in vivo PD animal model, compound (-)-8a exhibited efficacious anti-parkinsonian effect. (C) 2016 Elsevier Ltd. All rights reserved.